Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.73 |
| ▸ | RET | P07949 | 10/20 | 0.73 |
| ▸ | KIF5B | P33176 | 8/20 | 0.73 |
| ▸ | JAK3 | P52333 | 2/20 | 0.73 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 12/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.72 |
| ▸ | GAK | O14976 | 2/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.68 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.68 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.68 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 3/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864719 | 0.86 | KDR (0.82) | KDRRETKIF5BJAK3EGFR | |
| SCHEMBL7119275 | 0.85 | JAK3 (0.74) | KDRRETKIF5BJAK3MKNK1 | |
| SCHEMBL12485595 | 0.85 | KDR (0.83) | KDRRETKIF5BJAK3MKNK1 | |
| SCHEMBL6668470 | 0.84 | JAK3 (0.73) | KDRRETKIF5BJAK3MKNK1 | |
| SCHEMBL30925305 | 0.84 | JAK3 (1.00) | KDRRETKIF5BJAK3MKNK1 | |
| SCHEMBL323445 | 0.84 | JAK3 (1.00) | KDRRETKIF5BJAK3MKNK1 | |
| Whi-P131 SCHEMBL29295 | 0.81 | EGFR (1.00) | KDRRETKIF5BJAK3EGFR | |
| SCHEMBL5478005 | 0.81 | EGFR (1.00) | KDRRETKIF5BJAK3EGFR | |
| Whi-P131 SCHEMBL29369589 | 0.81 | EGFR (1.00) | KDRRETKIF5BJAK3EGFR | |
| SCHEMBL1483638 | 0.81 | EGFR (0.71) | KDRRETKIF5BJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | disclosed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | KDR 2810/4885RET 2800/4885KIF5B 3284/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | KDR 3004/4885RET 1370/4885KIF5B 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.